← Leaderboards
Jun Wang
Rutgers Biomedical And Health Sciences
$10,683,111
Attributed
$11,471,511
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,471,511 · 7
By mechanism
R01$9,479,763 · 4
R33$1,157,935 · 1
R21$833,813 · 2
Top collaborators
- Daniel R Perez5 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Edward V Arnold$28,950,124
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsPropertyLeadIn VivoIn VitroReportingDrug TargetingVirusVaccinesPharmaceutical PreparationsViralMedicalAntiviral AgentsStructureIndexingExperimental StudyMutationProteinsStructure-Activity RelationshipAnti-Viral EfficacyMutantPathogenic VirusMouse ModelPeptide Hydrolases
Grant awards (25)
Development of 2C inhibitors as broad-spectrum enterovirus antivirals$740,419
R01 · FY2025 · AI · contact PI
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals$713,864
R01 · FY2025 · AI · contact PI
Development of 2C inhibitors as broad-spectrum enterovirus antivirals$755,280
R01 · FY2024 · AI · contact PI
Drug target validation of the enterovirus D68 2A protease$630,155
R01 · FY2024 · AI · contact PI
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals$730,106
R01 · FY2023 · AI · contact PI
Drug target validation of the enterovirus D68 2A protease$709,111
R01 · FY2023 · AI · contact PI
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals$741,356
R01 · FY2022 · AI · contact PI
Drug target validation of the enterovirus D68 2A protease$720,664
R01 · FY2022 · AI · contact PI
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A proteases$409,619
R01 · FY2022 · AI · contact PI
Drug target validation of the enterovirus D68 2A protease$540,570
R01 · FY2021 · AI · contact PI
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals$392,655
R01 · FY2021 · AI · contact PI
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A proteases$380,542
R01 · FY2021 · AI · contact PI
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals$278,287
R01 · FY2021 · AI · contact PI
Drug target validation of the enterovirus D68 2A protease$169,835
R01 · FY2021 · AI · contact PI
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A Proteases$27,733
R01 · FY2021 · AI · contact PI
Drug target validation of the enterovirus D68 2A protease$660,405
R01 · FY2020 · AI · contact PI
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A Proteases$398,056
R01 · FY2020 · AI · contact PI
Discovery of broad-spectrum influenza antivirals with a high genetic barrier to drug resistance by targeting the viral polymerase$194,099
R21 · FY2020 · AI · contact PI
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A Proteases$481,106
R01 · FY2019 · AI · contact PI
Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel$378,908
R33 · FY2019 · AI · contact PI
Discovery of broad-spectrum influenza antivirals with a high genetic barrier to drug resistance by targeting the viral polymerase$220,848
R21 · FY2019 · AI · contact PI
Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel$381,355
R33 · FY2018 · AI · contact PI
Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel$397,672
R33 · FY2017 · AI · contact PI
Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel$211,279
R21 · FY2016 · AI · contact PI
Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel$207,587
R21 · FY2015 · AI · contact PI